• Next-generation stool DNA testing achieves 93.9% sensitivity for colorectal cancer versus 67.3% for FIT in head-to-head comparison

    A review of screening technologies found that while molecular testing has improved diagnostic performance, FIT remains the most cost-effective primary screening tool under real-world adherence conditions. (Frontiers in Medicine)